

HAWAII Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	1,386,000	1,412,400	1,438,700	1,466,000
Prediabetes	436,100	459,100	481,600	491,400
Diagnosed diabetes	97,800	118,000	135,200	148,700
Undiagnosed diabetes	51,300	58,800	63,900	66,600
Total with diabetes (diagnosed and undiagnosed)	149,100	176,800	199,100	215,300
Complications:				
Visual impairment	16,000	18,800	20,900	22,300
Renal failure	230	270	300	320
Leg amputations	200	220	240	240
Annual deaths attributable to diabetes	1,050	1,210	1,320	1,380
Total annual cost (2015 dollars)	\$1.7 B	\$2.0 B	\$2.3 B	\$2.5 B
Annual medical costs	\$1.2 B	\$1.4 B	\$1.6 B	\$1.8 B
Annual nonmedical costs	\$0.5 B	\$0.6 B	\$0.7 B	\$0.7 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	226,200	264,500	300,700	327,000
Prediabetes	115,400	134,900	153,400	166,700
Diagnosed diabetes	42,800	50,000	56,800	61,800
Undiagnosed diabetes	15,800	18,500	21,100	22,900
Total with diabetes (diagnosed and undiagnosed)	58,600	68,500	77,900	84,700
Complications:				
Visual impairment	8,000	9,100	10,100	10,700
Renal failure	130	150	160	170
Leg amputations	99	110	110	110
Annual deaths attributable to diabetes	730	810	860	870
Total annual cost (2015 dollars)	\$748 M	\$875 M	\$995 M	\$1.1 B
Annual medical costs	\$702 M	\$821 M	\$933 M	\$1.0 B
Annual nonmedical costs	\$46 M	\$54 M	\$62 M	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.